295 related articles for article (PubMed ID: 36834806)
1. Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.
Rusiñol L; Puig L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834806
[TBL] [Abstract][Full Text] [Related]
2. Deucravacitinib is an allosteric TYK2 protein kinase inhibitor FDA-approved for the treatment of psoriasis.
Roskoski R
Pharmacol Res; 2023 Mar; 189():106642. PubMed ID: 36754102
[TBL] [Abstract][Full Text] [Related]
3. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
Front Immunol; 2022; 13():884399. PubMed ID: 35693820
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
Krueger JG; McInnes IB; Blauvelt A
J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
[TBL] [Abstract][Full Text] [Related]
5. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
6. A novel highly selective allosteric inhibitor of tyrosine kinase 2 (TYK2) can block inflammation- and autoimmune-related pathways.
Chen CX; Zhang W; Qu S; Xia F; Zhu Y; Chen B
Cell Commun Signal; 2023 Oct; 21(1):287. PubMed ID: 37845748
[TBL] [Abstract][Full Text] [Related]
7. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
8. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
9. Progress on the Pharmacological Targeting of Janus Pseudokinases.
Henry SP; Jorgensen WL
J Med Chem; 2023 Aug; 66(16):10959-10990. PubMed ID: 37578217
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of TYK2 pseudokinase domain stabilizers that allosterically inhibit TYK2 signaling.
Locke GA; Muckelbauer J; Tokarski JS; Barbieri CM; Belić S; Falk B; Tredup J; Wang YK
Methods Enzymol; 2022; 667():685-727. PubMed ID: 35525559
[TBL] [Abstract][Full Text] [Related]
11. Triple-action inhibitory mechanism of allosteric TYK2-specific inhibitors.
Wang J; Batista VS; Bunick CG
bioRxiv; 2023 Oct; ():. PubMed ID: 37873392
[TBL] [Abstract][Full Text] [Related]
12. JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors.
Nogueira M; Puig L; Torres T
Drugs; 2020 Mar; 80(4):341-352. PubMed ID: 32020553
[TBL] [Abstract][Full Text] [Related]
13. Discovery of WD-890: A novel allosteric TYK2 inhibitor for the treatment of multiple autoimmune diseases.
Fang Z; Sun H; Wang Y; Sun Z; Yin M
Biomed Pharmacother; 2023 Nov; 167():115611. PubMed ID: 37778274
[TBL] [Abstract][Full Text] [Related]
14. Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.
Jensen LT; Attfield KE; Feldmann M; Fugger L
EBioMedicine; 2023 Nov; 97():104840. PubMed ID: 37863021
[TBL] [Abstract][Full Text] [Related]
15. Recent progress on tyrosine kinase 2 JH2 inhibitors.
Deng L; Wan L; Liao T; Wang L; Wang J; Wu X; Shi J
Int Immunopharmacol; 2023 Aug; 121():110434. PubMed ID: 37315371
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases.
Chang Y; Xu S; Ding K
J Med Chem; 2019 Oct; 62(20):8951-8952. PubMed ID: 31603320
[TBL] [Abstract][Full Text] [Related]
17. Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.
Martin G
Dermatol Ther (Heidelb); 2023 Feb; 13(2):417-435. PubMed ID: 36592300
[TBL] [Abstract][Full Text] [Related]
18. Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712.
Breinlinger E; Van Epps S; Friedman M; Argiriadi M; Chien E; Chhor G; Cowart M; Dunstan T; Graff C; Hardee D; Herold JM; Little A; McCarthy R; Parmentier J; Perham M; Qiu W; Schrimpf M; Vargo T; Webster MP; Wu F; Bennett D; Edmunds J
J Med Chem; 2023 Oct; 66(20):14335-14356. PubMed ID: 37823891
[TBL] [Abstract][Full Text] [Related]
19. Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis.
Leit S; Greenwood JR; Mondal S; Carriero S; Dahlgren M; Harriman GC; Kennedy-Smith JJ; Kapeller R; Lawson JP; Romero DL; Toms AV; Shelley M; Wester RT; Westlin W; McElwee JJ; Miao W; Edmondson SD; Masse CE
Bioorg Med Chem Lett; 2022 Oct; 73():128891. PubMed ID: 35842205
[TBL] [Abstract][Full Text] [Related]
20. Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.
Danese S; Peyrin-Biroulet L
Inflamm Bowel Dis; 2021 Nov; 27(12):2023-2030. PubMed ID: 34089259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
